The IKBKG Knockout HeLa Polyclonal Cells provide a CRISPR/Cas9-edited polyclonal HeLa cell population with targeted disruption of the IKBKG gene. This loss-of-function model eliminates expression of the NEMO scaffold, the essential regulatory subunit of the I??B kinase (IKK) complex. Supplied as a heterogeneous polyclonal pool, this product enables robust phenotypic screening without clonal artifacts.
HeLa cells are an immortalized epithelial cell line originally derived from cervical adenocarcinoma tissue of a 31-year-old African American woman. They are HPV18-positive and represent one of the most widely used models in cancer biology, signal transduction, and functional genomics. Their robust growth characteristics and genetic tractability make them a preferred host for CRISPR/Cas9-mediated gene disruption studies.
IKBKG encodes NEMO, the non-catalytic regulatory subunit of the I??B kinase (IKK) complex, which also contains the catalytic subunits IKK?? and IKK??. NEMO functions as an essential scaffold that integrates upstream signals from diverse receptors, including TNF receptor 1 (TNFR1), Toll-like receptor 4 (TLR4), and the interleukin-1 receptor (IL-1R). Upon ligand binding (e.g., TNF-??, LPS, IL-1??), adaptors such as TRAF6 and RIP1 recruit TAK1 kinase, which phosphorylates and activates the IKK complex. Active IKK, with NEMO as an indispensable organizer, phosphorylates I??B??, leading to its ubiquitination and proteasomal degradation. This releases NF-??B transcription factors (p65/p50) for nuclear translocation and transcriptional activation of target genes encoding pro-inflammatory cytokines (TNF, IL-6), anti-apoptotic proteins (Bcl-2, Bcl-xL), and cell adhesion molecules (ICAM-1). Negative regulators such as CYLD and A20 deubiquitinate key signaling intermediates to terminate NF-??B responses.
In HeLa cells, NF-??B signaling regulates diverse processes, including proliferation, survival, and inflammation. Disruption of IKBKG abolishes NEMO-dependent IKK activity, effectively silencing canonical NF-??B transcriptional responses. This knockout model renders HeLa cells unresponsive to stimuli that typically activate NF-??B, such as TNF-?? or IL-1??, and sensitizes them to apoptosis by downregulating anti-apoptotic Bcl-2 family members. Consequently, the IKBKG polyclonal knockout HeLa cells are a powerful tool for dissecting NF-??B-dependent gene expression programs and evaluating pathway dependencies in a cervical adenocarcinoma context.
These polyclonal knockout cells are ideal for a broad range of experimental applications. Researchers can employ Western blotting to confirm loss of NEMO protein and assess phosphorylation status of IKK substrates (p-I??B??, p-p65). RT-qPCR and NF-??B luciferase reporter assays enable quantitative analysis of transcriptional responses, while ELISA detects secretion of downstream cytokines such as TNF and IL-6. Apoptosis susceptibility can be measured using caspase-3/7 activity assays, and drug sensitivity screens can identify NF-??B-dependent chemoresistance. The heterogeneous polyclonal composition supports robust, reproducible phenotype assessment in functional genomics and pathway interrogation studies. For further details, please contact Ascent Research.
